Gabi is a structural biologist who used her PhD at the University of Cambridge to utilize high-powered computational approaches to probe how drugs interact with a class of disease-causing proteins in the body called disordered proteins. In particular, Gabi focused on studying disordered proteins involved in Alzheimer’s disease. Disordered proteins are challenging to target with drugs as they rapidly change their structure and lack traditional drug-binding pockets.

As a Schmidt Science Fellow, Gabi  worked with Prof. D Flemming Hansen at University College London, where she pivoted from computation into experimental structural biology to uncover the rules of drug binding to viral disordered proteins. In particular, she explored  Nuclear Magnetic Resonance Spectroscopy (NMR) which offers unparalleled accuracy to experimentally characterize disordered proteins and their interactions.

Gabi is the CEO/CSO and co-founder of Bind, a Focused Research Organisation (FRO) committed to improving patient outcomes by turning disordered proteins into viable drug targets.